<?xml version="1.0" encoding="UTF-8"?>
<p id="par0080">Hydroxychloroquine and chloroquine are other drugs that have a long history of clinical use and similar chemical structures and are often used for the treatment of malaria erythematosus and rheumatoid arthritis [
 <xref rid="bib0330" ref-type="bibr">66</xref>]. Lopinavir is another drug, which was administered and marketed in combination with ritonavir by Abbott under the brand name Kaletra in 2000. Lopinavir is a protease inhibitor with high specificity with HIV-1 protease [
 <xref rid="bib0335" ref-type="bibr">67</xref>]. Another drug, umifenovir, was first developed in Russia and used in Russia and China for the treatment of prophylaxis, infections associated with influenza A and B, and other arbovirus [
 <xref rid="bib0340" ref-type="bibr">68</xref>]. Favipiravir was developed by Fujifilm Toyama Chemical, Japan, in 2014, for treating avian influenza resistant to neuraminidase inhibitors [
 <xref rid="bib0345" ref-type="bibr">69</xref>]. Oseltamivir is used to treat influenza A and B. This drug targets the neuraminidase distributed on the surface of the influenza virus to inhibit the spread of the influenza virus in the human body [
 <xref rid="bib0350" ref-type="bibr">[70]</xref>, 
 <xref rid="bib0355" ref-type="bibr">[71]</xref>, 
 <xref rid="bib0360" ref-type="bibr">[72]</xref>]. 
 <xref rid="tbl0015" ref-type="table">Table 3</xref> presents the off-label drugs against SARS-CoV-2 and COVID-19.
</p>
